BIOCRYST PHARMACEUTICALS INC's ticker is BCRX and the CUSIP is 09058V103. A total of 120 filers reported holding BIOCRYST PHARMACEUTICALS INC in Q4 2016. The put-call ratio across all filers is 0.31 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2017 | $16,560,000 | -4.9% | 3,372,674 | +1.4% | 2.76% | -8.9% |
| Q3 2017 | $17,421,000 | -6.0% | 3,324,705 | -0.3% | 3.03% | -22.4% |
| Q2 2017 | $18,537,000 | -36.2% | 3,333,958 | -3.6% | 3.91% | -48.9% |
| Q1 2017 | $29,048,000 | +12.5% | 3,458,120 | -15.2% | 7.65% | -21.3% |
| Q4 2016 | $25,819,000 | +39.2% | 4,078,895 | -3.0% | 9.72% | +73.4% |
| Q3 2016 | $18,542,000 | +191.9% | 4,204,579 | +88.0% | 5.60% | +158.1% |
| Q2 2016 | $6,353,000 | +13.7% | 2,237,066 | +13.3% | 2.17% | +7.1% |
| Q1 2016 | $5,586,000 | -73.1% | 1,973,932 | -1.8% | 2.03% | -70.4% |
| Q4 2015 | $20,748,000 | -19.7% | 2,010,501 | -9.9% | 6.85% | -14.6% |
| Q3 2015 | $25,833,000 | -23.5% | 2,230,206 | -1.4% | 8.03% | -18.3% |
| Q2 2015 | $33,762,000 | +65.3% | 2,261,361 | 0.0% | 9.83% | +6.6% |
| Q1 2015 | $20,420,000 | -25.7% | 2,261,361 | 0.0% | 9.22% | -9.4% |
| Q4 2014 | $27,498,000 | – | 2,261,361 | – | 10.17% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| VHCP Management II, LLC | 6,071,142 | $38,430,000 | 18.43% |
| RTW INVESTMENTS, LP | 4,078,895 | $25,819,000 | 9.72% |
| VHCP Management, LLC | 1,155,104 | $7,312,000 | 7.86% |
| RA Capital Management | 2,989,795 | $18,925,000 | 2.68% |
| DLD Asset Management, LP | 1,258,700 | $7,967,000 | 2.61% |
| Avoro Capital Advisors LLC | 1,631,502 | $10,327,000 | 2.09% |
| Ghost Tree Capital, LLC | 1,150,000 | $7,280,000 | 1.75% |
| GREAT POINT PARTNERS LLC | 725,000 | $4,589,000 | 0.94% |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 3,237,734 | $20,495,000 | 0.84% |
| Baker Brothers Advisors | 10,963,944 | $69,402,000 | 0.68% |